en · de · es · fr · pt
sr9009-notes.peptides3626.com › Faq › Sr9009 Background And Mechanism — Hands-On Walkthrough

Sr9009 Background And Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2026-06-21 · last reviewed 2026-07-20 · Faq

A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Related pages on this site

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Further detail

Musculocutaneous and muscle flaps contain a layer of muscle to provide bulk that can fill a deeper defect. If skin cover is needed, a skin graft can be placed over top of it. Examples include gastrocnemius flaps, latissimus dorsi flaps, TRAM flaps, and transverse upper gracillis flaps. Bone flaps contain bone and are used when structural support is needed, such as in jaw reconstruction or fibula flaps. Omental flaps can be used in chest wall defects, and intestinal flaps can be used to reconstruct tubular structures like the esophagus.

==== Partially competitive ==== The mechanism of partially competitive inhibition is similar to that of non-competitive, except that the EIS complex has catalytic activity, which may be lower or even higher (partially competitive activation) than that of the enzyme–substrate (ES) complex. This inhibition typically displays a lower Vmax, but an unaffected Km value.

17α-OHP is the parent compound of a class of progestins referred to as the 17α-hydroxyprogesterone derivatives. Among others, this class of drugs includes chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate.

=== 18 March === President Putin visited Crimea on the ninth anniversary of the peninsula's annexation. The Black Sea Grain Initiative between Ukraine and Russia, which was due to expire on 18 March, was extended.

=== Hair loss disorder === The first LLLT (low-level laser device) device (at a wavelength of 635 nm) for androgenetic alopecia was approved by the FDA two decades ago. The FDA then approved a similar device (at a wavelength of 655 nm) for alopecia two years later, in 2009. Low-level laser therapy (LLLT) is the traditional FDA-approved therapy for hair loss disorders, while LEDT has become a more advanced treatment due to its safety and efficacy. The commonly used wavelengths targeting hair loss disorder are red and infrared. In-vivo studies show that the red-light LEDT at the wavelength of 655 nm contributes to dramatic improvements in the hair counts of androgenetic alopecia patients. A more recent study indicates a similar therapeutic effect of yellow-light LEDT on androgenetic alopecia and alopecia areata patients.

Sources: en.wikipedia.org

Background from the literature

CoWIN (Covid Vaccine Intelligence Network) is an Indian government web portal for COVID-19 vaccination registration, owned and operated by India's Ministry of Health and Family Welfare. It displays booking slots of COVID-19 vaccine available in the nearby areas and can be booked on the website. The site also provides vaccination certificates to the beneficiaries, which act as vaccine passports for the beneficiaries and can be stored in Digilocker. Users can access the platform via desktop, tablet, and mobile phones.

Jerome Kalman Sherman (August 14, 1925 – December 1, 2023) was an American biologist and credited as a founder of modern sperm banking and cryopreservation. Sherman was also a professor of biology at University of Arkansas for more than three decades.

Commonly employed tracers include 3-3H glucose (radioactive), 6,6 2H-glucose (stable), and 1-13C glucose (stable). Prior to initiating the hyperinsulinemic phase, a 3-hour tracer infusion allows for the determination of the basal rate of glucose production. Throughout the clamp, the plasma tracer concentrations facilitate the computation of whole-body insulin-stimulated glucose metabolism, as well as the production of glucose by the body. (i.e., endogenous glucose production).

Sun tea is frequently brewed in temperate areas by placing tea and room-temperature water together in a glass jar left outdoors in direct sunlight. Steeping times are necessarily long, two to four hours. Tea may also be brewed with no heat at all by simply immersing the tea bags or infuser in room-temperature water and allowing a period of several hours (typically overnight) for steeping. Since sun brewing occurs in a temperature range that can promote the development of bacteria, particularly Alcaligenes viscolactis, the Centers for Disease Control and the Tea Association of the U.S.A. Inc. suggest storing sun-brewed tea in the refrigerator and discarding it after 24 hours.

=== Extractable nuclear antigens === Extractable nuclear antigens (ENA) are a group of autoantigens that were originally identified as antibody targets in people with autoimmune disorders. They are termed ENA because they can be extracted from the cell nucleus with saline. The ENAs consist of ribonucleoproteins and non-histone proteins, named by either the name of the donor who provided the prototype serum (Sm, Ro, La, Jo), or the name of the disease setting in which the antibodies were found (SS-A, SS-B, Scl-70).

Sources: en.wikipedia.org

Reference notes

=== Murder of Spadafora and aftermath === Hugo Spadafora was a physician and political activist who had first clashed with Noriega when they were both members of Torrijos's government. Though an ally of Torrijos, he and Noriega had been personal enemies for a long time. Despite not being a member of the opposition, he became a vocal critic of Noriega after returning to Panama from Guatemala in 1981. Spadafora amassed evidence of corruption within the government by using his position as an ally of Torrijos to question Noriega's allies, including Rodriguez and Carlton. This included a lengthy conversation with Carlton in mid-1985 after his drug operations had collapsed due to conflicts over a missing shipment, and he had received negative publicity in the Panamanian press. In September 1985 he accused Noriega of having connections to drug trafficking and announced his intent to expose him. The drug trafficking charges threatened Noriega's support among his own constituency of middle class individuals who had benefited under his and Torrijos's government. According to writers R. M. Koster and Guillermo Sánchez, on an occasion when Spadafora was traveling by bus from Costa Rica to Panama, witnesses saw him being detained by the PDF after crossing the border. His decapitated body was later found wrapped in a United States Postal Service mail bag showing signs of brutal torture. Noriega was widely believed to be responsible for the murder, and according to Koster and Sánchez, the U.S. had intelligence implicating Noriega. On the day of Spadafora's arrest, the U.S.

== Taxonomy == HHV-6A and HHV-6B were recognized by the International Committee on Taxonomy of Viruses (ICTV) as distinct species in 2012. Human roseoloviruses include HHV-6A, HHV-6B and HHV-7. Herpesvirus was established as a genus in 1971 in the first report of the ICTV. This genus consisted of 23 viruses among 4 groups. In 1976, a second ICTV report was released in which this genus was elevated to the family level — the herpetoviridae. Because of possible confusion with viruses derived from reptiles, the family name was changed in the third report (1979) to herpesviridae. In this report, the family Herpesviridae was divided into 3 subfamilies (alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae) and 5 unnamed genera; 21 viruses were recognized as members of the family. In 2009, the order Herpesvirales was created. This was necessitated by the discovery that the herpes viruses of fish and molluscs are only distantly related to those of birds and mammals. Order Herpesvirales contains three families, the Herpesviridae, which contains the long-recognized herpesviruses of mammals, birds, and reptiles, plus two new families — the family Alloherpesviridae which incorporates herpes viruses of bony fish and frogs, and the family Malacoherpesviridae which contains viruses of molluscs. As of 2012, this order currently has 3 families, 4 subfamilies (1 unassigned), 18 genera (4 unassigned) and 97 species.

== Function == The Min proteins prevent the FtsZ ring from being placed anywhere but near the mid cell and are hypothesized to be involved in a spatial regulatory mechanism that links size increases prior to cell division to FtsZ polymerization in the middle of the cell.

=== Fraud === Tea is a common target of food fraud. Lower cost ingredients may be substituted for tea, or a tea may be adulterated with undeclared and possibly toxic colors and flavours. The origin of the tea, picking season, and the processing techniques may be intentionally misidentified. Tea powders which undergo additional processing are more susceptible to food fraud.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network